Zhejiang Haisen Pharmaceutical Co., Ltd.

SZSE:001367 Stock Report

Market Cap: CN¥3.0b

Zhejiang Haisen Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

Zhejiang Haisen Pharmaceutical has been growing earnings at an average annual rate of 10.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.7% per year. Zhejiang Haisen Pharmaceutical's return on equity is 9.2%, and it has net margins of 27.6%.

Key information

10.4%

Earnings growth rate

3.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.7%
Return on equity9.2%
Net Margin27.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

May 01
Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

Recent updates

Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

May 01
Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

Revenue & Expenses Breakdown

How Zhejiang Haisen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:001367 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244341203424
30 Jun 244151173323
31 Mar 244061133620
31 Dec 233971053619
30 Sep 23390973519
30 Jun 23405973418
31 Mar 234241043116
01 Jan 234231083316
30 Sep 224171083412
30 Jun 224141073611
31 Mar 224011013411
31 Dec 21389943312
31 Dec 20285632711
31 Dec 1926669439
31 Dec 1824759429

Quality Earnings: 001367 has high quality earnings.

Growing Profit Margin: 001367's current net profit margins (27.6%) are higher than last year (24.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 001367's earnings have grown by 10.4% per year over the past 5 years.

Accelerating Growth: 001367's earnings growth over the past year (23.7%) exceeds its 5-year average (10.4% per year).

Earnings vs Industry: 001367 earnings growth over the past year (23.7%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 001367's Return on Equity (9.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:43
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Haisen Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution